[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100514836":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":17,"armGroups":18,"interventions":23,"overallOfficials":13,"centralContacts":13,"locations":13,"responsibleParty":28,"collaborators":13,"id":30,"slug":13,"hasResults":31,"nctId":32,"briefTitle":33,"officialTitle":34,"acronym":35,"eligibilityCriteria":36,"healthyVolunteers":31,"sex":37,"minAge":38,"maxAge":13,"enrollmentInfo":39,"targetDuration":42,"studyType":43,"phases":13,"briefSummary":44,"conditions":45,"keywords":13,"overallStatus":47,"whyStopped":13,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":13},{"fullName":5,"class":6},"CerbaXpert","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"The prevalence of each STI will be assessed by the participant's positive or negative status for each pathogen, determined by the following screening tests:","HIV testing is based on finding antibodies to HIV-1 and HIV-2 and P24 antigen of the virus;\n\n* Hepatitis B screening is based on HBsAg (hepatitis B surface antigen) research;\n* Herpes screening is based on testing for antibodies to Herpes Simplex virus (HSV-1 and HSV-2);\n* Papilloma virus screening is based on the HPV-HR test from a smear on the cervix;\n* Chlamydia screening is based on a nucleic acid amplification (NAAT) test;\n* Gonorrhea screening is based on the identification of the bacteria on a urine sample or secretions from the vagina or cervix;\n* Screening for trichomoniasis is based on a molecular diagnosis that involves identifying the parasite's DNA from a genital or urinary sample;\n* The detection of syphilis is based on antibody research.","3 years",null,{"allocation":13,"interventionModel":13,"interventionModelDescription":13,"primaryPurpose":13,"observationalModel":15,"timePerspective":16,"maskingInfo":13},"COHORT","PROSPECTIVE","A cohort of 9,000 participants meeting all the inclusion criteria will be recruited. A participant identification list will be created and maintained at clinical investigation sites, linking the participant's personal data to the code assigned in the research. The identification list of participants will be kept on the research site in paper or digital format classified in the investigator binder.",[19],{"label":20,"type":13,"description":13,"interventionNames":21},"Adults",[22],"Diagnostic Test: Blood sample",[24],{"type":25,"name":26,"description":26,"armGroupLabels":27,"otherNames":13},"DIAGNOSTIC_TEST","Blood sample",[20],{"type":29,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100514836",false,"NCT05983679","Prevalence of Sexually Transmitted Infections (STIs) and Coinfections in the General Population","Prevalence of Sexually Transmitted Infections (STIs) and Co-infections in the General Population","PREMINF","Inclusion Criteria:\n\n* Subject, male or female, 18 years of age or older\n* Subject capable of understanding the purpose of the research having given their free and informed written consent\n* Subject presenting to the laboratory for a biological examination\n* Affiliated subject or beneficiary of a social security scheme\n\nExclusion Criteria:\n\n\\- Protected subject: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision","ALL","18 Years",{"count":40,"type":41},9000,"ESTIMATED","3 Years","OBSERVATIONAL","Prevalence of Sexually Transmitted Infections (STIs) and co-infections in the general population",[46],"HIV Infections","NOT_YET_RECRUITING","2024-04-12",{"date":50,"type":51},"2024-04-15","ACTUAL",{"date":53,"type":41},"2024-12-04",{"date":55,"type":41},"2026-09-04",{"name":5,"class":6}]